XML 28 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Information (Tables)
 9 Months Ended
Jan. 31, 2018
Segment Reporting [Abstract]  
Summary of Segment Activity
The following tables summarize, for the periods indicated, operating results by reportable segment (table in thousands):
Three Months Ended January 31, 2018
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
259

 
$
4,823

 
$
—

 
$
5,082

Direct cost of services
 
(220
)
 
(2,251
)
 
—

 
(2,471
)
Sales and marketing costs
 
(94
)
 
(526
)
 
—

 
(620
)
Other operating expenses
 
—

 
(1,013
)
 
(893
)
 
(1,906
)
Stock- based compensation expense (1)
 
—

 
—

 
(152
)
 
(152
)
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(55
)
 
$
1,033

 
$
(1,045
)
 
$
(67
)
 
Three Months Ended January 31, 2017
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
347

 
$
3,218

 
$
—

 
$
3,565

Direct cost of services
 
(320
)
 
(2,084
)
 
—

 
(2,404
)
Sales and marketing costs
 
(128
)
 
(591
)
 
—

 
(719
)
Other operating expenses
 
—

 
(953
)
 
(653
)
 
(1,606
)
Stock- based compensation expense (1)
 
—

 
—

 
(237
)
 
(237
)
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(101
)
 
$
(410
)
 
$
(890
)
 
$
(1,401
)
 
Nine Months Ended January 31, 2018
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
1,077

 
$
14,242

 
$
—

 
$
15,319

Direct cost of services
 
(870
)
 
(6,836
)
 
—

 
(7,706
)
Sales and marketing costs
 
(265
)
 
(1,550
)
 
—

 
(1,815
)
Other operating expenses
 
—

 
(3,152
)
 
(2,538
)
 
(5,690
)
Stock- based compensation expense (1)
 
—

 
—

 
(863
)
 
(863
)
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(58
)
 
$
2,704

 
$
(3,401
)
 
$
(755
)

Nine Months Ended January 31, 2017
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
1,354

 
$
10,337

 
$
—

 
$
11,691

Direct cost of services
 
(1,165
)
 
(5,916
)
 
—

 
(7,081
)
Sales and marketing costs
 
(397
)
 
(1,778
)
 
—

 
(2,175
)
Other operating expenses
 
—

 
(3,043
)
 
(1,911
)
 
(4,954
)
Stock- based compensation expense (1)
 
—

 
—

 
(1,901
)
 
(1,901
)
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(208
)
 
$
(400
)
 
$
(3,812
)
 
$
(4,420
)

(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments. See Note 3 for the allocation of stock compensation expense relative to the individual line items as it is reported on the Company's Consolidated Statements of Operations.